Kiniksa Pharmaceuticals International, plc KNSA Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's net unrealized gains (losses) on securities still held?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported net unrealized gains (losses) on securities still held of -$640K in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's net unrealized gains (losses) on securities still held changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's net unrealized gains (losses) on securities still held decreased by 31900.0% year-over-year, from -$2K to -$640K.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's net unrealized gains (losses) on securities still held?
- Over 3 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's net unrealized gains (losses) on securities still held has grown at a 62.8% compound annual growth rate (CAGR), from -$32K to $138K.
- What does net unrealized gains (losses) on securities still held mean?
- Reflects the change in value of investment securities held by the company that have not yet been sold. These gains or losses are recognized in equity rather than the income statement, representing potential future liquidity or volatility. Tracking this metric is crucial for understanding the impact of market fluctuations on the company's balance sheet and investment portfolio.